ZA200707901B - Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same - Google Patents

Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same

Info

Publication number
ZA200707901B
ZA200707901B ZA200707901A ZA200707901A ZA200707901B ZA 200707901 B ZA200707901 B ZA 200707901B ZA 200707901 A ZA200707901 A ZA 200707901A ZA 200707901 A ZA200707901 A ZA 200707901A ZA 200707901 B ZA200707901 B ZA 200707901B
Authority
ZA
South Africa
Prior art keywords
same
pharmaceutical compositions
compositions containing
pyridine derivatives
novel imidazo
Prior art date
Application number
ZA200707901A
Other languages
English (en)
Inventor
Alcouffe Chantal
Badorc Alain
Bono Francoise
Bordes Marie-Francoise
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of ZA200707901B publication Critical patent/ZA200707901B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
ZA200707901A 2005-03-16 2006-03-15 Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same ZA200707901B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0502590A FR2883286B1 (fr) 2005-03-16 2005-03-16 NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, INHIBITEURS DE FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT

Publications (1)

Publication Number Publication Date
ZA200707901B true ZA200707901B (en) 2009-01-28

Family

ID=35276198

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200707901A ZA200707901B (en) 2005-03-16 2006-03-15 Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same

Country Status (24)

Country Link
US (2) US8008321B2 (xx)
EP (1) EP1861403B1 (xx)
JP (1) JP5007295B2 (xx)
KR (1) KR101278374B1 (xx)
CN (2) CN102050821A (xx)
AT (1) ATE556074T1 (xx)
AU (1) AU2006224466B2 (xx)
BR (1) BRPI0607589A2 (xx)
CA (1) CA2599643C (xx)
CY (1) CY1112997T1 (xx)
DK (1) DK1861403T3 (xx)
EA (1) EA013408B1 (xx)
ES (1) ES2386643T3 (xx)
FR (1) FR2883286B1 (xx)
IL (1) IL185611A (xx)
MA (1) MA29716B1 (xx)
MX (1) MX2007011361A (xx)
NO (1) NO20075169L (xx)
NZ (1) NZ561205A (xx)
PL (1) PL1861403T3 (xx)
PT (1) PT1861403E (xx)
SI (1) SI1861403T1 (xx)
WO (1) WO2006097625A1 (xx)
ZA (1) ZA200707901B (xx)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200804284A (en) * 2006-03-31 2008-01-16 Speedel Experimenta Ag Process for preparing 6,7-dihydro-5H-imidazo[1,5-a]pyridin-8-one
EP2118101B1 (en) 2007-03-09 2012-09-26 Probiodrug AG Imidazo [1,5-a] pyridine derivatives as inhibitors of glutaminyl cyclase
JP2010523668A (ja) 2007-04-10 2010-07-15 ハー・ルンドベック・アクチエゼルスカベット Ｐ２ｘ７拮抗薬としてのヘテロアリールアミド類似体
CA2720343A1 (en) * 2008-04-04 2009-10-08 Takeda Pharmaceutical Company Limited Heterocyclic derivative and use thereof
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
FR2962438B1 (fr) 2010-07-06 2012-08-17 Sanofi Aventis Derives d'indolizines, procedes de preparation et application en therapeutique
FR2962437B1 (fr) * 2010-07-06 2012-08-17 Sanofi Aventis Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
FR2967412B1 (fr) * 2010-11-17 2012-12-14 Sanofi Aventis Nouveaux derives d'indolizine, leur preparation et leur application en therapeutique
CN103548392B (zh) 2011-07-01 2018-07-06 诺基亚技术有限公司 用于向连接装置提供网络访问的方法和装置
FR2985185B1 (fr) * 2012-01-04 2013-12-27 Sanofi Sa Utilisation en therapeutique de derives d'imidazopyridine
WO2014005150A1 (en) * 2012-06-29 2014-01-03 Novartis Ag Crystalline forms of l-(2-((lr,3s,5r)-3-( (2 -fluoro-3 - (trifluoromethoxy) phenyl) carbamoyl) - 2 -azabicycl o [3.1.0] hexan- 2 -yl) - 2 -oxoethyl) - 5 -methyl - 1h - pyrazolo [3, 4 -c] pyridine - 3 - carboxami de and salts thereof
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
MX2015002959A (es) * 2013-03-10 2015-06-05 Univ Nagoya Nat Univ Corp Agente terapeutico para padecimiento sistemico oseo y uso del mismo.
EP3080101A1 (en) 2013-12-10 2016-10-19 Cleave Biosciences, Inc. Monocyclic pyrimidine/pyridine compounds as inhibitors of p97 complex
CN103910643B (zh) * 2014-04-23 2015-07-15 温州大学 一种抗癌活性甲酮衍生物、合成方法及其用途
FR3022244B1 (fr) * 2014-06-17 2016-07-01 Centre Nat De La Rech Scient (Cnrs) Utilisation d'un nouveau compose 3-aryl-4-catechol-pyrrole-n-propanol et ses derives pour le traitement du cancer et des pathologies associees a une angiogenese excessive
MX369646B (es) 2014-08-18 2019-11-15 Eisai R&D Man Co Ltd Sal de derivado de piridina monociclico y su cristal.
CN107922396B (zh) * 2015-07-20 2022-08-05 建新公司 集落刺激因子-1受体(csf-1r)抑制剂
WO2019189241A1 (ja) 2018-03-28 2019-10-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝細胞癌治療剤
CN110483437B (zh) * 2018-05-14 2022-12-06 嘉兴维眸生物科技有限公司 一种含五元环的化合物及其制备和应用
CN110183442A (zh) * 2019-06-06 2019-08-30 无锡合全药业有限公司 一种1 -(乙氧羰基)咪唑并[1, 5]吡啶-6-羧酸的合成方法
EP4267573A1 (en) 2020-12-23 2023-11-01 Genzyme Corporation Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors
CN113735849B (zh) * 2021-07-22 2022-10-11 安徽中医药大学 1-氰基咪唑并[1,5-a]吡啶类化合物及其合成方法
CN113603687A (zh) * 2021-08-02 2021-11-05 北京工业大学 一种氰基取代的咪唑[1,5-a]并吡啶合成新方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5738647A (en) * 1996-09-27 1998-04-14 Becton Dickinson And Company User activated iontophoretic device and method for activating same
FR2838123B1 (fr) * 2002-04-04 2005-06-10 Sanofi Synthelabo Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf
FR2896247B1 (fr) * 2006-01-13 2008-02-29 Sanofi Aventis Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique

Also Published As

Publication number Publication date
WO2006097625A1 (fr) 2006-09-21
CN102050821A (zh) 2011-05-11
PL1861403T3 (pl) 2012-10-31
FR2883286B1 (fr) 2008-10-03
US20080108648A1 (en) 2008-05-08
BRPI0607589A2 (pt) 2009-09-15
NZ561205A (en) 2009-09-25
CA2599643A1 (fr) 2006-09-21
IL185611A (en) 2013-11-28
IL185611A0 (en) 2008-01-06
US8633216B2 (en) 2014-01-21
CY1112997T1 (el) 2016-04-13
SI1861403T1 (sl) 2012-08-31
KR20070113227A (ko) 2007-11-28
AU2006224466B2 (en) 2012-02-16
JP2008533111A (ja) 2008-08-21
EP1861403A1 (fr) 2007-12-05
US20110136856A1 (en) 2011-06-09
ATE556074T1 (de) 2012-05-15
MX2007011361A (es) 2007-11-12
EA013408B1 (ru) 2010-04-30
NO20075169L (no) 2007-12-12
ES2386643T3 (es) 2012-08-24
KR101278374B1 (ko) 2013-06-25
PT1861403E (pt) 2012-07-20
CN101160309A (zh) 2008-04-09
FR2883286A1 (fr) 2006-09-22
EP1861403B1 (fr) 2012-05-02
DK1861403T3 (da) 2012-08-13
AU2006224466A1 (en) 2006-09-21
EA200701991A1 (ru) 2008-02-28
JP5007295B2 (ja) 2012-08-22
CA2599643C (fr) 2014-02-11
US8008321B2 (en) 2011-08-30
MA29716B1 (fr) 2008-09-01

Similar Documents

Publication Publication Date Title
ZA200707901B (en) Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same
MXPA05012025A (es) Imidazo y tiazolopiridinas como inhibidores de cinasa jak3.
WO2004074244A3 (en) Pyrimidine compounds
TW200801003A (en) Novel compounds
WO2007090141A3 (en) Pyrrolo [2, 3, b] pyridine derivatives useful as raf kinase inhibitors
TW200613243A (en) Novel compounds
TW200800999A (en) Novel compounds
WO2006011050A3 (en) Pyridine derivatives
TW200616995A (en) Novel compounds
SE0202539D0 (sv) Compounds
CA2603830A1 (en) PYRIDINE [2,3-B] PYRAZINONES
AU2002305143A1 (en) Pyrazolo'1,5-a!pyridine derivatives
WO2003095455A3 (en) Substituted pyrazolopyrimidines
WO2002048147A3 (en) Pyrazolopyridines
TW200639156A (en) New compounds
GEP20115231B (en) 2-amino-7,8-dihydro-6h-pyrido [4,3-d] pyrimidin-5-ones
TW200738659A (en) Novel compounds
TW200626553A (en) Novel compounds
TW200605888A (en) Novel compounds
MX2007007027A (es) Derivados piperazinilpiridina como agentes anti-obesidad.
IL191751A0 (en) Pyrrolo[2,3-c]pyridine derivatives
HK1145172A1 (en) (aza)indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor
SI1730144T1 (sl) Substituirane spojine 1,4,8-triazaspiro(4.5)dekan-2-on
SI1869038T1 (sl) Substituirane 5,6,7,8-tetrahidro-imidazo(1,2-a)piridin-2-ilaminske spojine in njihova uporaba za pripravo zdravil
TNSN07440A1 (en) Derivatives of pyrido [2,3 -d] pyrimidine, the preparation thereof, and the therapeutic application of the same